What is INTENSITY THERAPEUTICS INC's earnings per share (EPS)?

INTENSITY THERAPEUTICS INC (INTS) reported diluted earnings per share of $-8.56 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

INTENSITY THERAPEUTICS INC Financials

INTS

Source SEC Filings (10-K/10-Q) Updated Mar 27, 2026 Currency USD FYE March

This page shows INTENSITY THERAPEUTICS INC (INTS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Neutral

4/9

INTENSITY THERAPEUTICS INC passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.80x

For every $1 of reported earnings, INTENSITY THERAPEUTICS INC generates $0.80 in operating cash flow (-$9.2M OCF vs -$11.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$11.6M

YoY+28.7%

INTENSITY THERAPEUTICS INC reported -$11.6M in net income in fiscal year 2025. This represents an increase of 28.7% from the prior year.

EPS (Diluted)

$-8.56

INTENSITY THERAPEUTICS INC earned $-8.56 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 631.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$11.9M

YoY+360.3%

INTENSITY THERAPEUTICS INC held $11.9M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

INTENSITY THERAPEUTICS INC had 3M shares outstanding in fiscal year 2025. This represents a decrease of 83.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-97.7%

YoY+459.8pp

INTENSITY THERAPEUTICS INC's ROE was -97.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 459.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$6.8M

YoY-35.4%

INTENSITY THERAPEUTICS INC invested $6.8M in research and development in fiscal year 2025. This represents a decrease of 35.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

INTS Income Statement

Metric	FY25	FY24	FY23	FY22
Revenue	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
R&D Expenses	$6.8M-35.4%	$10.5M+119.3%	$4.8M-6.7%	$5.1M
SG&A Expenses	$5.2M-14.8%	$6.1M+72.3%	$3.5M+46.1%	$2.4M
Operating Income	-$12.0M+27.8%	-$16.6M-99.4%	-$8.3M-10.2%	-$7.5M
Interest Expense	N/A	$0-100.0%	$305K+272.0%	$82K
Income Tax	N/A	$0	$0	$0
Net Income	-$11.6M+28.7%	-$16.3M-54.4%	-$10.5M-39.0%	-$7.6M
EPS (Diluted)	$-8.56	$-1.17+15.2%	$-1.38	$-2.22

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.6M+0.8%	$1.5M-29.6%	$2.2M	N/A	$2.2M-39.6%	$3.6M+26.6%	$2.8M	N/A
SG&A Expenses	$1.2M+1.4%	$1.2M-3.4%	$1.2M	N/A	$1.4M-5.8%	$1.5M-21.9%	$1.9M	N/A
Operating Income	-$2.7M-1.0%	-$2.7M+20.3%	-$3.4M	N/A	-$3.6M+29.6%	-$5.1M-6.9%	-$4.7M	N/A
Interest Expense	N/A	N/A	N/A	N/A	$0	$0	$0	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.7M-5.3%	-$2.5M+24.2%	-$3.3M	N/A	-$3.5M+29.3%	-$5.0M-8.0%	-$4.6M	N/A
EPS (Diluted)	$-0.06+53.8%	$-0.13	$-0.22	N/A	$-0.25+30.6%	$-0.36-5.9%	$-0.34	N/A

INTS Balance Sheet

Metric	FY25	FY24	FY23	FY22
Total Assets	$14.1M+194.8%	$4.8M-72.3%	$17.3M+884.3%	$1.8M
Current Assets	$12.7M+277.9%	$3.4M-78.3%	$15.5M+965.7%	$1.5M
Cash & Equivalents	$11.9M+360.3%	$2.6M-69.7%	$8.6M+552.1%	$1.3M
Inventory	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A
Total Liabilities	$2.2M+19.3%	$1.9M-54.9%	$4.1M-75.5%	$16.9M
Current Liabilities	$2.1M+22.3%	$1.8M-55.7%	$4.0M-41.9%	$6.8M
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	$11.9M+307.0%	$2.9M-77.8%	$13.2M+187.2%	-$15.1M
Retained Earnings	-$78.4M-17.4%	-$66.8M-32.2%	-$50.5M-30.7%	-$38.7M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$9.6M+115.7%	$4.4M+45.0%	$3.1M-35.9%	$4.8M-8.2%	$5.2M-39.9%	$8.7M-30.1%	$12.4M-28.3%	$17.3M
Current Assets	$8.2M+169.5%	$3.0M+84.0%	$1.7M-50.9%	$3.4M-11.2%	$3.8M-49.1%	$7.4M-33.4%	$11.2M-27.8%	$15.5M
Cash & Equivalents	$7.1M+218.9%	$2.2M+138.5%	$929K-64.1%	$2.6M-6.9%	$2.8M-14.2%	$3.2M-56.5%	$7.5M-12.8%	$8.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.4M+4.6%	$2.3M-17.3%	$2.7M+46.4%	$1.9M-23.4%	$2.4M-26.9%	$3.3M+23.9%	$2.7M-35.0%	$4.1M
Current Liabilities	$2.3M+5.2%	$2.2M-17.7%	$2.6M+49.8%	$1.8M-24.3%	$2.3M-27.7%	$3.2M+27.2%	$2.5M-36.4%	$4.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$7.2M+230.7%	$2.2M+553.9%	$334K-88.6%	$2.9M+5.0%	$2.8M-48.0%	$5.3M-45.0%	$9.7M-26.1%	$13.2M
Retained Earnings	-$75.3M-3.7%	-$72.7M-3.6%	-$70.1M-5.0%	-$66.8M-5.0%	-$63.6M-5.8%	-$60.1M-9.0%	-$55.1M-9.1%	-$50.5M

INTS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22
Operating Cash Flow	-$9.2M+39.3%	-$15.2M-111.2%	-$7.2M-31.6%	-$5.5M
Capital Expenditures	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A
Investing Cash Flow	$6.4M0.0%	$6.4M+205.5%	-$6.0M	$0
Financing Cash Flow	$18.6M+540.1%	$2.9M-85.8%	$20.5M+809.9%	$2.3M
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$2.4M+2.8%	-$2.5M-23.5%	-$2.0M+25.4%	-$2.7M+32.8%	-$4.0M+5.7%	-$4.2M+3.5%	-$4.4M-361.5%	-$946K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0	$0	$0	$0-100.0%	$3.1M+51766.7%	-$6K-100.2%	$3.3M+15.6%	$2.8M
Financing Cash Flow	$7.2M+93.4%	$3.7M+1041.2%	$328K-86.8%	$2.5M+499.5%	$413K+13666.7%	$3K-62.5%	$8K+161.5%	-$13K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

INTS Financial Ratios

Metric	FY25	FY24	FY23	FY22
Gross Margin	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A
Return on Equity	-97.7%+459.8pp	-557.5%-477.4pp	-80.1%	N/A
Return on Assets	-82.3%+257.8pp	-340.1%-279.2pp	-60.9%+370.6pp	-431.5%
Current Ratio	5.92+4.0	1.92-2.0	3.91+3.7	0.21
Debt-to-Equity	0.19-0.5	0.64+0.3	0.31+1.4	-1.12
FCF Margin	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-37.0%+79.2pp	-116.2%+885.9pp	-1002.1%	N/A	-126.4%-33.4pp	-93.0%-45.7pp	-47.3%	N/A
Return on Assets	-27.9%+29.2pp	-57.1%+52.1pp	-109.2%	N/A	-67.4%-10.1pp	-57.3%-20.2pp	-37.1%	N/A
Current Ratio	3.60+2.2	1.40+0.8	0.63-1.3	1.92+0.3	1.63-0.7	2.32-2.1	4.43+0.5	3.91
Debt-to-Equity	0.33-0.7	1.03-7.1	8.18+7.5	0.64-0.2	0.88+0.3	0.62+0.3	0.28-0.0	0.31
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Moleculin Biotec MBRX

$12.2M

Ernexa ERNA

$5.8M

Lyra Therapeutics, Inc. LYRA

$2.3M

Sensei Biotherapeutics, Inc. SNSE

$39.8M

Bolt Biotherapeutics, Inc. BOLT

$7.8M

Frequently Asked Questions

Is INTENSITY THERAPEUTICS INC profitable?

No, INTENSITY THERAPEUTICS INC (INTS) reported a net income of -$11.6M in fiscal year 2025.

What is INTENSITY THERAPEUTICS INC's return on equity (ROE)?

INTENSITY THERAPEUTICS INC (INTS) has a return on equity of -97.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is INTENSITY THERAPEUTICS INC's operating cash flow?

INTENSITY THERAPEUTICS INC (INTS) generated -$9.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are INTENSITY THERAPEUTICS INC's total assets?

INTENSITY THERAPEUTICS INC (INTS) had $14.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does INTENSITY THERAPEUTICS INC spend on research and development?

INTENSITY THERAPEUTICS INC (INTS) invested $6.8M in research and development during fiscal year 2025.

How many shares does INTENSITY THERAPEUTICS INC have outstanding?

INTENSITY THERAPEUTICS INC (INTS) had 3M shares outstanding as of fiscal year 2025.

What is INTENSITY THERAPEUTICS INC's current ratio?

INTENSITY THERAPEUTICS INC (INTS) had a current ratio of 5.92 as of fiscal year 2025, which is generally considered healthy.

What is INTENSITY THERAPEUTICS INC's debt-to-equity ratio?

INTENSITY THERAPEUTICS INC (INTS) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is INTENSITY THERAPEUTICS INC's return on assets (ROA)?

INTENSITY THERAPEUTICS INC (INTS) had a return on assets of -82.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is INTENSITY THERAPEUTICS INC's cash runway?

Based on fiscal year 2025 data, INTENSITY THERAPEUTICS INC (INTS) had $11.9M in cash against an annual operating cash burn of $9.2M. This gives an estimated cash runway of approximately 15 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is INTENSITY THERAPEUTICS INC's Piotroski F-Score?

INTENSITY THERAPEUTICS INC (INTS) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are INTENSITY THERAPEUTICS INC's earnings high quality?

INTENSITY THERAPEUTICS INC (INTS) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.